Eculizumab Monotherapy for NMOSD: Data from PREVENT and Its Open-label Extension

Overview

Journal Mult Scler

Publisher Sage Publications

Specialty Neurology

Date 2021 Sep 9

PMID 34498507

Citations 12

Authors

Sean J Pittock

Kazuo Fujihara

Jacqueline Palace

Achim Berthele

Ho Jin Kim

Celia Oreja-Guevara

Ichiro Nakashima

Michael Levy

Shulian Shang

Marcus Yountz

Larisa Miller

Roisin Armstrong

Dean M Wingerchuk

Affiliations

Soon will be listed here.

Abstract

During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks-5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan-Meier analysis; 95% confidence interval, 75.7-99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.

Citing Articles

Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody-associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis,....

Tahara M, Awaya T, Saito K, Sawada H Front Immunol. 2025; 16:1551379.

PMID: 40070831 PMC: 11893387. DOI: 10.3389/fimmu.2025.1551379.

Inflammatory Demyelinating Diseases of the Central Nervous System.

Li M, Liu Q Adv Neurobiol. 2024; 41:171-218.

PMID: 39589715 DOI: 10.1007/978-3-031-69188-1_8.

C3a Mediates Endothelial Barrier Disruption in Brain-Derived, but Not Retinal, Human Endothelial Cells.

Wolf H, Guempelein L, Schikora J, Pauly D Int J Mol Sci. 2024; 25(20).

PMID: 39457022 PMC: 11508547. DOI: 10.3390/ijms252011240.

Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.

Preziosa P, Amato M, Battistini L, Capobianco M, Centonze D, Cocco E J Neurol. 2024; 271(7):3879-3896.

PMID: 38771385 DOI: 10.1007/s00415-024-12426-w.

Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

Tisavipat N, Juan H, Chen J Saudi J Ophthalmol. 2024; 38(1):2-12.

PMID: 38628414 PMC: 11017007. DOI: 10.4103/sjopt.sjopt_102_23.

References

Pittock S, Berthele A, Fujihara K, Kim H, Levy M, Palace J . Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(7):614-625. DOI: 10.1056/NEJMoa1900866. View

Frampton J . Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder. Drugs. 2020; 80(7):719-727. PMC: 7183484. DOI: 10.1007/s40265-020-01297-w. View

Hillmen P, Muus P, Roth A, Elebute M, Risitano A, Schrezenmeier H . Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013; 162(1):62-73. PMC: 3744747. DOI: 10.1111/bjh.12347. View

Socie G, Caby-Tosi M, Marantz J, Cole A, Bedrosian C, Gasteyger C . Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019; 185(2):297-310. PMC: 6594003. DOI: 10.1111/bjh.15790. View

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn R, Illa I . Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019; 60(1):14-24. PMC: 6619057. DOI: 10.1002/mus.26447. View